Small Animal Model Systems for Studying Hepatitis B Virus Replication and Pathogenesis

Maura Dandri; Marc Lutgehetmann; Tassilo Volz; Jörg Petersen

doi:10.1055/s-2006-939760

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2006; 26(2): 181-191
DOI: 10.1055/s-2006-939760

Small Animal Model Systems for Studying Hepatitis B Virus Replication and Pathogenesis

Maura Dandri¹ , Marc Lutgehetmann¹ , Tassilo Volz¹ , Jörg Petersen¹

¹Department of Medicine, University Hospital Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany

Abstract

ABSTRACT

The lack of reliable in vitro infection systems and convenient animal models has hindered progress in hepatitis B virus (HBV) research and the development of new treatment options. Due to various restraints encountered using chimpanzees and other models of HBV infection that are based on HBV-related viruses, and due to the necessity to work with small and well-characterized animal systems, it is not surprising that most recent developments have focused on mice. Various strains of transgenic mice harboring the entire HBV genome, or selected viral genes, were developed and proved to be very useful to elucidate mechanisms of HBV replication and pathogenesis. Furthermore, novel, exciting alternative mouse models have been developed recently, which allow not only studies on viral replication, but also the investigation of mechanisms of viral entry and clearance. This article provides an overview and discussion of the different mouse models of HBV replication and infection that are currently available.

KEYWORDS

Hepatitis B virus - transgenic mice - severe combined immunodeficiency - trimera - urokinase plasminogen activator mice

Full Text

References

REFERENCES

1 Chen M, Sallberg M, Hughes J et al.. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol. 2005; 79 3016-3027
2 Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004; 127(suppl 1) S56-S61
3 Bruns M, Miska S, Chassot S, Will H. Enhancement of hepatitis B virus infection by noninfectious subviral particles. J Virol. 1998; 72 1462-1468
4 Sells M A, Chen M L, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1987; 84 1005-1009
5 Galle P R, Hagelstein J, Kommerell B, Volkmann M, Schranz P, Zentgraf H. In vitro experimental infection of primary human hepatocytes with hepatitis B virus. Gastroenterology. 1994; 106 664-673
6 Gripon P, Diot C, Guguen-Guillouzo C. Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology. 1993; 192 534-540
7 Gripon P, Diot C, Theze N et al.. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol. 1988; 62 4136-4143
8 Schulze-Bergkamen H, Untergasser A, Dax A et al.. Primary human hepatocytes-a valuable tool for investigation of apoptosis and hepatitis B virus infection. J Hepatol. 2003; 38 736-744
9 Gripon P, Rumin S, Urban S et al.. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A. 2002; 99 15655-15660
10 Jaeschke H. Are cultured liver cells the right tool to investigate mechanisms of liver disease or hepatotoxicity?. Hepatology. 2003; 38 1053-1055
11 Barker L F, Chisari F V, McGrath P P et al.. Transmission of type B viral hepatitis to chimpanzees. J Infect Dis. 1973; 127 648-662
12 Bertoni R, Sette A, Sidney J et al.. Human class I supertypes and CTL repertoires extend to chimpanzees. J Immunol. 1998; 161 4447-4455
13 Will H, Cattaneo R, Koch H G et al.. Cloned HBV DNA causes hepatitis in chimpanzees. Nature. 1982; 299 740-742
14 Berthelot P, Courouce A M, Eyquem A et al.. Hepatitis B vaccine safety monitoring in the chimpanzee: interpretation of results. J Med Primatol. 1984; 13 119-133
15 Ohmura T, Ohmizu A, Sumi A et al.. Properties of recombinant hepatitis B vaccine. Biochem Biophys Res Commun. 1987; 149 1172-1178
16 Fujisawa Y, Kuroda S, Van Eerd P M, Schellekens H, Kakinuma A. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre- S2 + S) protein particles (a third generation vaccine). Vaccine. 1990; 8 192-198
17 Ogata N, Cote P J, Zanetti A R et al.. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology. 1999; 30 779-786
18 Baumert T F, Yang C, Schurmann P et al.. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology. 2005; 41 247-256
19 von Weizsacker F, Kock J, MacNelly S, Ren S, Blum H E, Nassal M. The tupaia model for the study of hepatitis B virus: direct infection and HBV genome transduction of primary tupaia hepatocytes. Methods Mol Med. 2004; 96 153-161
20 Lin E, Luscombe C, Colledge D, Wang Y Y, Locarnini S. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 1998; 42 2132-2137
21 Nicoll A J, Colledge D L, Toole J J, Angus P W, Smallwood R A, Locarnini S A. Inhibition of duck hepatitis B virus replication by 9-(2- phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother. 1998; 42 3130-3135
22 Korba B E, Cote P J, Menne S et al.. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther. 2004; 9 937-952
23 Foster W K, Miller D S, Scougall C A, Kotlarski I, Colonno R J, Jilbert A R. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection. J Virol. 2005; 79 5819-5832
24 Summers J, Mason W S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell. 1982; 29 403-415
25 Chen H S, Kaneko S, Girones R et al.. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol. 1993; 67 1218-1226
26 Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol. 1994; 68 2026-2030
27 Dandri M, Schirmacher P, Rogler C E. Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication. J Virol. 1996; 70 5246-5254
28 Summers J, Jilbert A R, Yang W et al.. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A. 2003; 100 11652-11659
29 Summers J, Mason W S. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci U S A. 2004; 101 638-640
30 Mason W S, Jilbert A R, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A. 2005; 102 1139-1144
31 Chisari F V, Pinkert C A, Milich D R et al.. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science. 1985; 230 1157-1160
32 Araki K, Miyazaki J, Hino O et al.. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci U S A. 1989; 86 207-211
33 Kim C M, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991; 351 317-320
34 Guidotti L G, Matzke B, Schaller H, Chisari F V. High-level hepatitis B virus replication in transgenic mice. J Virol. 1995; 69 6158-6169
35 Guidotti L G, Rochford R, Chung J, Shapiro M, Purcell R, Chisari F V. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999; 284 825-829
36 Julander J G, Colonno R J, Sidwell R W, Morrey J D. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Antiviral Res. 2003; 59 155-161
37 Julander J G, Sidwell R W, Morrey J D. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 2002; 55 27-40
38 Weber O, Schlemmer K H, Hartmann E et al.. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. 2002; 54 69-78
39 Kimura K, Kakimi K, Wieland S, Guidotti L G, Chisari F V. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol. 2002; 76 10702-10707
40 Kakimi K, Lane T E, Wieland S et al.. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med. 2001; 194 1755-1766
41 Uprichard S L, Boyd B, Althage A, Chisari F V. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci U S A. 2005; 102 773-778
42 Chang J, Taylor J M. Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action. J Virol. 2003; 77 9728-9731
43 Shlomai A, Shaul Y. RNA interference: small RNAs effectively fight viral hepatitis. Liver Int. 2004; 24 526-531
44 Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology. 2003; 37 764-770
45 Moriyama T, Guilhot S, Klopchin K et al.. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science. 1990; 248 361-364
46 Guidotti L G, Guilhot S, Chisari F V. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J Virol. 1994; 68 1265-1270
47 Guidotti L G, Matzke B, Pasquinelli C, Schoenberger J M, Rogler C E, Chisari F V. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol. 1996; 70 7056-7061
48 Guidotti L G, Ishikawa T, Hobbs M V, Matzke B, Schreiber R, Chisari F V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996; 4 25-36
49 Heise T, Guidotti L G, Cavanaugh V J, Chisari F V. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J Virol. 1999; 73 474-481
50 Wieland S F, Vega R G, Muller R et al.. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol. 2003; 77 1227-1236
51 Sitia G, Isogawa M, Iannacone M, Campbell I L, Chisari F V, Guidotti L G. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest. 2004; 113 1158-1167
52 Larkin J, Clayton M, Sun B et al.. Hepatitis B virus transgenic mouse model of chronic liver disease. Nat Med. 1999; 5 907-912
53 Baron J L, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity. 2002; 16 583-594
54 Petersen J, Dandri M, Burkle A, Zhang L, Rogler C E. Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair. J Virol. 1997; 71 5455-5463
55 Dandri M, Burda M R, Burkle A et al.. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology. 2002; 35 217-223
56 Chisari F V, Filippi P, McLachlan A et al.. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol. 1986; 60 880-887
57 Chisari F V, Filippi P, Buras J et al.. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A. 1987; 84 6909-6913
58 Bouchard M J, Schneider R J. The enigmatic X gene of hepatitis B virus. J Virol. 2004; 78 12725-12734
59 Slagle B L, Lee T H, Medina D, Finegold M J, Butel J S. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol Carcinog. 1996; 15 261-269
60 Koike K, Moriya K, Iino S et al.. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology. 1994; 19 810-819
61 Ueda H, Ullrich S J, Gangemi J D et al.. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet. 1995; 9 41-47
62 Delaney W E, Isom H C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology. 1998; 28 1134-1146
63 Sprinzl M F, Oberwinkler H, Schaller H, Protzer U. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. J Virol. 2001; 75 5108-5118
64 Ren S, Nassal M. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. J Virol. 2001; 75 1104-1116
65 Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci U S A. 1995; 92 10099-10103
66 Hofmann C, Strauss M. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther. 1998; 5 531-536
67 Isogawa M, Kakimi K, Kamamoto H, Protzer U, Chisari F V. Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology. 2005; 333 293-300
68 Feitelson M A, DeTolla L J, Zhou X D. A chronic carrierlike state is established in nude mice injected with cloned hepatitis B virus DNA. J Virol. 1988; 62 1408-1415
69 Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999; 6 1258-1266
70 Yang P L, Althage A, Chung J, Chisari F V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A. 2002; 99 13825-13830
71 Klein C, Bock C T, Wedemeyer H et al.. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology. 2003; 125 9-18
72 McCaffrey A P, Nakai H, Pandey K et al.. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol. 2003; 21 639-644
73 Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther. 2003; 8 769-776
74 Morrissey D V, Lockridge J A, Shaw L et al.. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005; 23 1002-1007
75 Ilan E, Burakova T, Dagan S et al.. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology. 1999; 29 553-562
76 Eren R, Ilan E, Nussbaum O et al.. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology. 2000; 32 588-596
77 Bocher W O, Galun E, Marcus H et al.. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse. Hepatology. 2000; 31 480-487
78 Bocher W O, Dekel B, Schwerin W et al.. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol. 2001; 31 2071-2079
79 Ohashi K, Marion P L, Nakai H et al.. Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med. 2000; 6 327-331
80 Brown J J, Parashar B, Moshage H et al.. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. Hepatology. 2000; 31 173-181
81 Gupta S, Bhargava K K, Novikoff P M. Mechanisms of cell engraftment during liver repopulation with hepatocyte transplantation. Semin Liver Dis. 1999; 19 15-26
82 Sandgren E P, Palmiter R D, Heckel J L, Daugherty C C, Brinster R L, Degen J L. Complete hepatic regeneration after somatic deletion of an albumin- plasminogen activator transgene. Cell. 1991; 66 245-256
83 Rhim J A, Sandgren E P, Degen J L, Palmiter R D, Brinster R L. Replacement of diseased mouse liver by hepatic cell transplantation. Science. 1994; 263 1149-1152
84 Overturf K, Al-Dhalimy M, Tanguay R et al.. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet. 1996; 12 266-273
85 Mignon A, Guidotti J E, Mitchell C et al.. Selective repopulation of normal mouse liver by Fas/CD95-resistant hepatocytes. Nat Med. 1998; 4 1185-1188
86 Shinkai Y, Rathbun G, Lam K P et al.. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992; 68 855-867
87 Petersen J, Dandri M, Gupta S, Rogler C E. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1998; 95 310-315
88 Dandri M, Burda M R, Torok E et al.. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology. 2001; 33 981-988
89 Meuleman P, Libbrecht L, De Vos R et al.. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology. 2005; 41 847-856
90 Mercer D F, Schiller D E, Elliott J F et al.. Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001; 7 927-933
91 Tateno C, Yoshizane Y, Saito N et al.. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol. 2004; 165 901-912
92 Tsuge M, Hiraga N, Takaishi H et al.. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology. 2005; 42 1046-1054
93 Dandri M, Burda M R, Zuckerman D M et al.. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol. 2005; 42 54-60

Jörg PetersenM.D.

I. Medizinische Klinik und Poliklinik, Universitatsklinikum Hamburg-Eppendorf, Martinistr

52, D-20246, Hamburg, Germany